Brad O’Connor has been Managing Director and Chief Executive Officer of Cogstate Limited since December 2005. He has responsibility for Cogstate’s overall strategic direction and day-to-day operations as well as development of expansion opportunities outside of the core clinical trials business.
Martyn Myer AO
Martyn Myer is Chairman of Cogstate Limited. Until 30 June 2007 he was President of the Howard Florey Institute of Experimental Physiology and Medicine and was a director of the Florey Neuroscience Institutes until May 2009. In 2008, Mr Myer was awarded the title of Officer of the Order of Australia for service to business and the community.
David Dolby is an independent investor representing the Dolby Family Trust on a variety of technology investments in pharmaceutical research and drug development, health monitoring devices, computer vision, aerospace, consumer media and entertainment technologies, as well as philanthropic ventures for the Ray and Dagmar Dolby Family Fund.
Richard van den Broek
Mr van den Broek is founder and managing partner of HSMR Advisors LLC, a U.S. based fund manager with an investment emphasis on small and mid-cap biotech public companies. From 2000 through 2003 he was a Partner at Cooper Hill Partners, LLC, an investment fund focused on the healthcare sector.
Dr. Mohs retired from Eli Lilly in 2015, where he held several leadership positions. Before joining Eli Lilly in 2002, Dr. Mohs spent 23 years with the Mount Sinai School of Medicine in NY where he was Professor in the Department of Psychiatry and Associate Chief of Staff for Research at the Bronx Veterans Affairs Medical Center.
Ms Player brings deep healthcare sector experience and strong commercial expertise to the Board of Cogstate. She has held senior executive roles with Healthscope Ltd, a leading private healthcare provider in Australia, including the former positions of Group Executive – Legal, Governance and Sustainability, and General Counsel and Company Secretary from 2005 until 2019.